Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

Biotech company Regeneron (NASDAQ:REGN) will be reporting results this Thursday before the bell. Here’s what you need to know.

Regeneron beat analysts’ revenue expectations last quarter, reporting revenues of $3.61 billion, up 19% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates.

Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Regeneron’s revenue to grow 3.8% year on year, in line with the 3.6% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Regeneron rarely misses Wall Street’s revenue estimates.

Looking at Regeneron’s peers in the biotechnology segment, only Incyte has reported results so far. It exceeded analysts’ revenue estimates, delivering year-on-year sales growth of 37.7%.

There has been positive sentiment among investors in the biotechnology segment, with share prices up 4.4% on average over the last month. Regeneron is up 10.1% during the same time and is heading into earnings with an average analyst price target of $819.25 (compared to the current share price of $695.88).

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.